Granted U.S. Patent from PTSD Discovery Programme

AI SummaryClose X

Solvonis Therapeutics plc has been granted a U.S. patent, U.S. Patent No. 12,590,077, for a monoamine modulator compound series from its post-traumatic stress disorder (PTSD) discovery program, which targets serotonin, dopamine, and noradrenaline transporters. This composition-of-matter patent provides strong protection for the underlying compounds and strengthens the long-term value of the PTSD program, an area with significant unmet need and growing commercial interest, as evidenced by Otsuka Pharmaceutical's potential $1.225 billion acquisition of Transcend Therapeutics. The patent supports a broader chemistry platform beyond a single asset, offering flexibility for future development, including the lead candidate SVN-114.

Disclaimer*

UK 100

Latest directors dealings